Promising β-catenin data sparks clinical opportunity for Parabilis

In the quest to drug the undruggable, the transcription regulator β-catenin has lagged the success seen with KRAS, but new data this week may point to a breakthrough.

At the European Society of Medical Oncology (ESMO) Congress on Monday, Parabilis Medicines Inc. reported that its stapled α-helical peptide, FOG-001, was effective against desmoid tumors. On Friday, it built on those results with evidence that the therapy has activity in other cancers driven by β-catenin...